Meeting
2019 ASCO Annual Meeting
Safety of intravenous (IV) NEPA and oral NEPA for prevention of CINV in patients (pts) with breast cancer (BC) receiving anthracycline/cyclophosphamide (AC) chemotherapy (CT).
Authors
Lee S. Schwartzberg
West Cancer Center, Memphis, TN
Lee S. Schwartzberg , Daniel Voisin , Giada Rizzi , Kamal Patel , Matti S. Aapro
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Palliative Care and Symptom Management
Clinical Trial Registration Number
NCT03403712
Citation
J Clin Oncol 37, 2019 (suppl; abstr 11594)
DOI
10.1200/JCO.2019.37.15_suppl.11594
Abstract #
11594
Poster Bd #
286
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Olanzapine with or without an NK-1 receptor antagonist for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy: A phase III randomized, double-blind, placebo-controlled trial (ALLIANCE A221602).
First Author: Rudolph M. Navari
Poster
2019 Supportive Care in Oncology Symposium
Antiemetic efficacy of intravenous (IV) NEPA in patients with breast cancer (BC) receiving anthracycline/cyclophosphamide (AC) chemotherapy.
First Author: Lee S. Schwartzberg
Poster
2018 Palliative and Supportive Care in Oncology Symposium
Efficacy of intravenous (IV) NEPA, a fixed NK1/5-HT3 receptor antagonist combination, for prevention of emesis following highly emetogenic chemotherapy (HEC).
First Author: Eric Roeland
Poster
2016 ASCO Annual Meeting
Rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer.
First Author: Lee Steven Schwartzberg